Abstract
Next-generation sequencing (NGS) is rapidly becoming routine in clinical oncology practice to identify therapeutic biomarkers, including gene rearrangements in anaplastic lymphoma kinase (ALK). Our study investigated the concordance of ALK positivity evaluated by DNA-based NGS with orthogonal ALK testing methods such as fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), and RNA-based NGS (RNA-NGS). Thirty-eight patients with lung adenocarcinoma who were detected with ALK rearrangements using DNA-NGS and also had adequate tissue samples submitted for FISH, IHC, and RNA-NGS, were included in this study. Of the 38 patients, RNA samples from 3 patients failed quality control for RNA-NGS. The concordance of ALK positivity was calculated relative to DNA-NGS results. The concordance rates were 97.1% (34/35) for RNA-NGS, 94.7% (36/38) for IHC, and 97.4% (37/38) for FISH. DNA-NGS detected single ALK rearrangements in 14 (35.0%) patients and complex ALK rearrangements in 26 (65.0%). RNA-NGS detected only single transcripts of the primary ALK fusions. A novel LANCL1-ALK (L7:A20) detected using DNA-NGS was detected as EML4-ALK (E13:A20) transcripts using RNA-NGS. Interestingly, patients with single ALK rearrangements were more likely to be detected with atypical isolated red signals (p < 0.001), while patients with complex ALK rearrangements were more likely to be detected with atypical split red and green signals less than 2 signal diameters apart (p < 0.001). Our study highlights the reliability of NGS in the accurate detection of specific ALK fusion variants and concomitant mutations that are crucial for individualized treatment decisions in patients with lung cancer.
Similar content being viewed by others
Data availability
All authors confirm adherence to the policy. All datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Abbreviations
- ALK:
-
Anaplastic lymphoma kinase
- EML4:
-
Echinoderm microtubule-associated protein-like 4
- FDA:
-
Food and Drug Administration
- FFPE:
-
Formalin-fixed, paraffin-embedded
- FISH:
-
Fluorescence in situ hybridization
- IHC:
-
Immunohistochemistry
- NGS:
-
Next-generation sequencing
- NSCLC:
-
Non-small-cell lung cancer
- qRT-PCR:
-
Quantitative reverse transcriptase-polymerase chain reaction
- TKI:
-
Tyrosine kinase inhibitor
References
Soda M et al (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448(7153):561–566
Kwak EL et al (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363(18):1693–1703
Vidal J et al (2014) Assessment of ALK status by FISH on 1000 Spanish non-small cell lung cancer patients. J Thorac Oncol 9(12):1816–1820
Li W et al (2017) Combinational analysis of FISH and immunohistochemistry reveals rare genomic events in ALK fusion patterns in NSCLC that responds to crizotinib treatment. J Thorac Oncol 12(1):94–101
Tian P et al (2020) Unique molecular features and clinical outcomes in young patients with non-small cell lung cancer harboring ALK fusion genes. J Cancer Res Clin Oncol 146(4):935–944
Sabir SR et al (2017) EML4-ALK variants: biological and molecular properties, and the implications for patients. Cancers (Basel) 9(9):118
Ou SI, Zhu VW, Nagasaka M (2020) Catalog of 5’ fusion partners in ALK-positive NSCLC Circa 2020. JTO Clin Res Rep 1(1):100015
Shaw AT et al (2013) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368(25):2385–2394
Camidge DR et al (2019) Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase III ALEX study. J Thorac Oncol 14(7):1233–1243
Uruga H, Mino-Kenudson M (2018) ALK (D5F3) CDx: an immunohistochemistry assay to identify ALK-positive NSCLC patients. Pharmgenomics Pers Med 11:147–155
Conde E et al (2016) Profile of Ventana ALK (D5F3) companion diagnostic assay for non-small-cell lung carcinomas. Expert Rev Mol Diagn 16(6):707–713
Takeuchi K et al (2008) Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res 14(20):6618–6624
Wu YC et al (2013) Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in Taiwan. PLoS ONE 8(8):e70839
Teixido C et al (2014) Concordance of IHC, FISH and RT-PCR for EML4-ALK rearrangements. Transl Lung Cancer Res 3(2):70–74
Letovanec I et al (2018) Evaluation of NGS and RT-PCR methods for ALK rearrangement in European NSCLC patients: results from the European Thoracic Oncology Platform Lungscape Project. J Thorac Oncol 13(3):413–425
Dacic S et al (2016) ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma. Oncotarget 7(50):82943–82952
Zeng L et al (2020) Comparison of next-generation sequencing and ventana immunohistochemistry in detecting ALK rearrangements and predicting the efficacy of first-line crizotinib in patients with advanced non-small cell lung cancer. Onco Targets Ther 13:7101–7109
Wynes MW et al (2014) An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators. J Thorac Oncol 9(5):631–638
Ilie MI et al (2015) Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK ‘borderline’-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategies. Ann Oncol 26(1):238–244
Pekar-Zlotin M et al (2015) Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer. Oncologist 20(3):316–322
Rosenbaum JN et al (2018) Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer. Mod Pathol 31(5):791–808
Tao Z et al (2021) Profiling receptor tyrosine kinase fusions in Chinese breast cancers. Front Oncol 11:741142
**ang C et al. (2022) Identification and validation of noncanonical RET fusions in non-small-cell lung cancer through DNA and RNA sequencing. J Mol Diagn
Dobin A et al (2013) STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29(1):15–21
Haas BJ et al (2019) Accuracy assessment of fusion transcript detection via read-map** and de novo fusion transcript assembly-based methods. Genome Biol 20(1):213
Camidge DR et al (2012) Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer. Cancer 118(18):4486–4494
Camidge DR et al (2010) Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res 16(22):5581–5590
Sasaki T et al (2010) The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer 46(10):1773–1780
Guyard A et al (2019) Isolated 5’ signals are an atypical pattern to be considered as positive for ALK rearrangement: a brief report of three cases and review of the literature. Transl Oncol 12(5):784–787
Minca EC et al (2013) ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH. J Mol Diagn 15(3):341–346
Zacharias M et al (2021) Reflex testing in non-small cell lung carcinoma using DNA- and RNA-based next-generation sequencing-a single-center experience. Transl Lung Cancer Res 10(11):4221–4234
Benayed R et al (2019) High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no mitogenic driver alteration detected by DNA sequencing and low tumor mutation burden. Clin Cancer Res 25(15):4712–4722
Cohen D et al (2020) Optimizing mutation and fusion detection in NSCLC by sequential DNA and RNA sequencing. J Thorac Oncol 15(6):1000–1014
Solomon BJ et al (2014) First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371(23):2167–2177
Li Y et al (2018) Response to crizotinib in advanced ALK-rearranged non-small cell lung cancers with different ALK-fusion variants. Lung Cancer 118:128–133
Yoshida T et al (2016) Differential crizotinib response duration among ALK fusion variants in ALK-positive non-small-cell lung cancer. J Clin Oncol 34(28):3383–3389
Woo CG et al (2017) Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer. Ann Oncol 28(4):791–797
Choi YL et al (2008) Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res 68(13):4971–4976
Zhang Y et al (2020) Detection of nonreciprocal/reciprocal ALK translocation as poor predictive marker in patients with first-line crizotinib-treated ALK-rearranged NSCLC. J Thorac Oncol 15(6):1027–1036
Li W et al (2020) Intergenic breakpoints identified by DNA sequencing confound targetable kinase fusion detection in NSCLC. J Thorac Oncol 15(7):1223–1231
Zhang SS et al (2021) Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC. Lung Cancer 158:126–136
Kron A et al (2018) Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer. Ann Oncol 29(10):2068–2075
Song P et al (2019) Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK-rearranged non-small-cell lung cancer. Cancer Med 8(4):1551–1557
Zhang C et al (2019) Neoadjuvant crizotinib in resectable locally advanced non-small cell lung cancer with ALK rearrangement. J Thorac Oncol 14(4):726–731
Li W et al (2021) Guidelines for clinical practice of ALK fusion detection in non-small-cell lung cancer: a proposal from the Chinese RATICAL study group. J National Cancer Cent 1(4):123–131
Mosele F et al (2020) Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol 31(11):1491–1505
Zhou F, Zhou C (2018) Lung cancer in never smokers-the East Asian experience. Transl Lung Cancer Res 7(4):450–463
Acknowledgements
The authors would like to thank all the patients and their families for their cooperation and support. We also thank the investigators, study coordinators, operation staff, and the whole project team who worked on this project. We would also like to extend our utmost appreciation for the active support of the staff of Burning Rock Biotech, particularly Drs. Analyn Lizaso, Dejian Gu, Bing Li, Haiyan Li, Wenjie Sun, Zhou Zhang, and **g Lin.
Funding
This study was supported by grants from the National Natural Science Foundation of China (82172991, 81502089 to Y.D., 81773109 to Z.Z.), the Natural Science Foundation of Jiangsu Province (BK20151024 to Y.D., BK20151582 to Z.Z.), and the Natural Science Research Program for Higher Education in Jiangsu Province (21KJB320015 to Y.D.).
Author information
Authors and Affiliations
Contributions
Zhi-Hong Zhang and Ying Ding conceived the study and drafted the manuscript. Zhi-Hong Zhang and Ying Ding acquired funding. All the authors collected and analyzed the clinical data and participated in the data interpretation, data analysis, and manuscript writing and editing. All the authors contributed in the revision and approved the final manuscript.
Corresponding author
Ethics declarations
Ethical approval and consent to participate
All procedures performed in studies involving human participants were performed in accordance with the Declaration of Helsinki. This study was approved by the Ethics Committee of the First Affiliated Hospital of Nan**g Medical University.
Consent for publication
Not applicable.
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Ding, Y., Sun, C., Su, W. et al. Detecting anaplastic lymphoma kinase (ALK) gene rearrangements with next-generation sequencing remains a reliable approach in patients with non-small-cell lung cancer. Virchows Arch 481, 405–419 (2022). https://doi.org/10.1007/s00428-022-03339-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00428-022-03339-y